These results suggest that the HDACs indeed play an important role in XPC gene silencing for both HTB4 and HTB9 bladder cancer cells, and treatment with the VPA HDAC inhibitor causes activation of the XPC transcription in both bladder cancer cell lines. Here, XPC is linked to urinary bladder carcinoma.